All Articles
-
RevolKa announces the closing of ￥250 million series A extension funding to accelerate Drug-Discovery programs
-
RevolKa Started joint research of a drug discovery program for rare diseases
-
RevolKa launched a drug discovery program for rare diseases
-
RevolKa completed the contract research with SEKISUI CHEMICAL CO., LTD
-
RevolKa Signed Master Service Agreement with Daiichi Sankyo
-
La Jolla Institute for Immunology and RevolKa started a Research Collaboration
-
Presentation movie uploaded at Antibody Engineering & Therapeutics 2023
-
RevolKa raises ￥150 million series A extension
-
SEKISUI CHEMICAL CO., LTD. and RevolKa Signed a Contract Research Agreement
-
Presenting at Antibody Engineering & Therapeutics